REGISTERED
on 29 Mar 2022
Last Applicant/ Owned by
228 East 45th Street, Suite 9E
New York
NY
10017
Serial Number
87765139 filed on 22nd Jan 2018
Registration Number
6681763 registered on 29th Mar 2022
Correspondent Address
HOPE V. SHOVEIN
Filing Basis
1. intent to use
Disclaimer
NO DATA
EBI EXPONENTIAL BIOTHERAPIES
biopharmaceutical and pharmaceutical research; conducting clinical trials for others in the fields of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; scientific research of medicines, synthetic peptides and synthetic peptidomimetics as they relate Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
biopharmaceutical and pharmaceutical research; conducting clinical trials for others in the fields of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; scientific research of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, biopharmaceuticals and pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; development, testing, and inspection of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals; laboratory services relating to medicines, synthetic peptides, synthetic peptidomimetics, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals, namely, research in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; laboratory analysis in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; medical research in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; scientific research for medical purposes in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs
Class [040]
Treatment & Processing of Materials Services
custom manufacture of medicines, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals; treatment of biopharmaceutical and pharmaceutical materials being medicines, biopharmaceutical and pharmaceutical compounds, synthetic peptides and synthetic peptidomimetics; processing of medicines, biopharmaceutical and pharmaceutical compounds, synthetic peptides and synthetic peptidomimetics for others; custom manufacture of medical devices for others
Class [005]
Pharmaceutical Products
medicines, namely, medicines for alleviating or treating vasculogenic disease, medicines for alleviating or treating hemodynamic instabilities, medicines for alleviating or treating diabetes, medicines for alleviating or treating of immune system related diseases and disorders; pharmaceutical drugs, namely, pharmaceutical preparations for alleviating or treating vasculogenic disease, pharmaceutical preparations alleviating or treating hemodynamic instabilities, pharmaceutical preparations for alleviating or treating diabetes, pharmaceutical preparations for alleviating or treating of immune system related diseases and disorders; biopharmaceutical drugs, namely, biopharmaceutical preparations for alleviating or treating vasculogenic disease, biopharmaceutical preparations for alleviating or treating hemodynamic instabilities, biopharmaceutical preparations for alleviating or treating diabetes, biopharmaceutical preparations for alleviating or treating of immune system related diseases and disorders; biopharmaceuticals, namely, biopharmaceuticals for alleviating or treating vasculogenic disease, biopharmaceuticals alleviating or treating hemodynamic instabilities, biopharmaceuticals for alleviating or treating diabetes, biopharmaceuticals for alleviating or treating of immune system related diseases and disorders; synthetic peptides for biopharmaceutical purposes and for pharmaceutical purposes, namely, synthetic peptides for alleviating or treating vasculogenic disease, synthetic peptides for alleviating or treating hemodynamic instabilities, synthetic peptides for alleviating or treating diabetes, synthetic peptides for alleviating or treating of immune system related diseases and disorders; synthetic peptidemimetics for biopharmaceutical purposes and for pharmaceutical purposes, namely, sytnthetic peptidomimetics for alleviating or treating vasculogenic disease, synthetic peptidomimetics for alleviating or treating hemodynamic instabilities, synthetic peptidomimetics for alleviating or treating diabetes, synthetic peptidomimetics for alleviating or treating of immune system related diseases and disorders
Mark Details
Serial Number
No 87765139
Mark Type
No Service Mark
Attorney Docket Number
No ELZ0222TUS
44D Filed
Yes
44D Current
No
44E filed
No
44E Current
Yes
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Design Code(s)
26.01.03 -
Incomplete circles (more than semi-circles)
26.05.21 -
Triangles that are completely or partially shaded
26.17.09 -
Curved line(s), band(s) or bar(s)
26.19.01 -
Spheres
Legal History
| Status Date | Action Taken |
|---|---|
| 29th Mar 2022 | REGISTERED-PRINCIPAL REGISTER |
| 11th Jan 2022 | PUBLISHED FOR OPPOSITION |
| 11th Jan 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 22nd Dec 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 07th Dec 2021 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| 02th Dec 2021 | EXAMINERS AMENDMENT -WRITTEN |
| 02th Dec 2021 | EXAMINERS AMENDMENT E-MAILED |
| 02th Dec 2021 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| 02th Dec 2021 | EXAMINER'S AMENDMENT ENTERED |
| 02th Dec 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |